H

Hangzhou AGS MedTech Co Ltd
SSE:688581

Watchlist Manager
Hangzhou AGS MedTech Co Ltd
SSE:688581
Watchlist
Price: 60.47 CNY -5.07% Market Closed
Market Cap: 4.9B CNY
Have any thoughts about
Hangzhou AGS MedTech Co Ltd?
Write Note

Hangzhou AGS MedTech Co Ltd
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hangzhou AGS MedTech Co Ltd
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
H
Hangzhou AGS MedTech Co Ltd
SSE:688581
Short-Term Debt
ÂĄ5.6m
CAGR 3-Years
19%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Short-Term Debt
ÂĄ70m
CAGR 3-Years
88%
CAGR 5-Years
46%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Short-Term Debt
ÂĄ428.7m
CAGR 3-Years
24%
CAGR 5-Years
33%
CAGR 10-Years
24%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Short-Term Debt
ÂĄ3.5m
CAGR 3-Years
N/A
CAGR 5-Years
-15%
CAGR 10-Years
N/A
J
Jafron Biomedical Co Ltd
SZSE:300529
Short-Term Debt
ÂĄ338.8m
CAGR 3-Years
N/A
CAGR 5-Years
73%
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Short-Term Debt
ÂĄ328.2m
CAGR 3-Years
-24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hangzhou AGS MedTech Co Ltd
Glance View

Market Cap
4.9B CNY
Industry
Health Care

Hangzhou AGS MedTech Co., Ltd. engages in the research and development, manufacture, and sale of equipment in minimally invasive diagnosis and treat. The company is headquartered in Hangzhou, Zhejiang and currently employs 501 full-time employees. The company went IPO on 2023-05-19. The firm's main products are used in the field of digestive endoscopy diagnosis and treatment, and are divided into hemostatic closure, EMR/ESD, biopsy, ERCP and diagnosis and treatment instruments according to their therapeutic purposes. The hemostatic closure category includes clip devices and single-use bipolar high-frequency hemostats. Medical instruments include high-frequency surgical equipment, carbon dioxide gas supply devices for endoscopes, and water supply devices for endoscopes. The biopsy category includes single-use biopsy forceps and single-use graspers.

Intrinsic Value
86.8 CNY
Undervaluation 30%
Intrinsic Value
Price
H

See Also

What is Hangzhou AGS MedTech Co Ltd's Short-Term Debt?
Short-Term Debt
5.6m CNY

Based on the financial report for Dec 31, 2023, Hangzhou AGS MedTech Co Ltd's Short-Term Debt amounts to 5.6m CNY.

What is Hangzhou AGS MedTech Co Ltd's Short-Term Debt growth rate?
Short-Term Debt CAGR 3Y
19%

Over the last year, the Short-Term Debt growth was 0%. The average annual Short-Term Debt growth rates for Hangzhou AGS MedTech Co Ltd have been 19% over the past three years .

Back to Top